Condition P09

Metabolic dysfunction associated steatotic liver disease or steatohepatitis

Adults with MASLD or biopsy confirmed MASH (formerly NAFLD and NASH).

18 randomized trials; 18 fitted analyses across 16 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

Resolution of steatohepatitis without worsening of fibrosisprimary

O60

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 48 to 104 (target week 72)	Treatment policy	Each dose separately	2	5	Network meta-analysis
weeks 48 to 104 (target week 72)	Treatment policy	Doses of a drug pooled	2	2	Pairwise meta-analysis

Fibrosis improvement without worsening of steatohepatitisprimary

O61

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 48 to 104 (target week 72)	Treatment policy	Doses of a drug pooled	2	2	Pairwise meta-analysis
weeks 48 to 104 (target week 72)	Treatment policy	Each dose separately	2	5	Network meta-analysis
weeks 48 to 104 (target week 72)	Hypothetical (as if everyone stayed on treatment)	Doses of a drug pooled	1	2	Descriptive only
weeks 48 to 104 (target week 72)	Hypothetical (as if everyone stayed on treatment)	Each dose separately	1	4	Descriptive only

SF-36 physical component summary change

O24A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 20 to 130 (target week 52)	Treatment policy	Each dose separately	1	4	Descriptive only
weeks 20 to 130 (target week 52)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	5	9	Network meta-analysis

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	4	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	7	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	5	9	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	5	9	Network meta-analysis

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	5	9	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	5	9	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis

Discontinuation due to gastrointestinal adverse events

O27E

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	4	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	9	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	1	2	Descriptive only

Acute pancreatitis

O29

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately	2	5	Descriptive only

Medullary thyroid carcinoma

O32A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Suicidal ideation or behavior

O35A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Death by suicide

O35B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	3	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately	3	8	Descriptive only

Pancreatic cancer

O38

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Acute kidney injury

O121

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only